Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Franck, Sebastian"'
Autor:
Franck, Sebastian.
Univ., Diss.--München, 2005.
Externí odkaz:
http://www.gbv.de/dms/sbb-berlin/495797960.pdf
Autor:
Franck, Sebastian, Fuhrmann-Selter, Tania, Joseph, Jan F., Michelet, Robin, Casilag, Fiordiligie, Sirard, Jean-Claude, Wicha, Sebastian G., Kloft, Charlotte
Publikováno v:
In Talanta 15 August 2019 201:253-258
Autor:
Casilag, Fiordiligie, Matarazzo, Laura, Franck, Sebastian, Figeac, Martin, Michelet, Robin, Kloft, Charlotte, Carnoy, Christophe, Sirard, Jean-Claude
Publikováno v:
ACS Infectious Diseases
ACS Infectious Diseases, 2021, Online ahead of print. ⟨10.1021/acsinfecdis.1c00176⟩
ACS Infectious Diseases, American Chemical Society, 2021, Online ahead of print. ⟨10.1021/acsinfecdis.1c00176⟩
ACS Infectious Diseases, 2021, Online ahead of print. ⟨10.1021/acsinfecdis.1c00176⟩
ACS Infectious Diseases, American Chemical Society, 2021, Online ahead of print. ⟨10.1021/acsinfecdis.1c00176⟩
International audience; Alternative treatment strategies against bacterial infections are required to decrease the use of antibiotics. This study tested the hypothesis that stimulation of the innate immune receptor Toll-like receptor 4 can be combine
Autor:
Michelet, Robin, Ursino, Moreno, Boulet, Sandrine, Franck, Sebastian, Casilag, Fiordiligie, Baldry, Mara, Rolff, Jens, van Dyk, Madelé, Wicha, Sebastian, Sirard, Jean-Claude, Comets, Emmanuelle, Zohar, Sarah, Kloft, Charlotte
Publikováno v:
Pharmaceutics
Pharmaceutics, 2021, 13 (5), pp.601. ⟨10.3390/pharmaceutics13050601⟩
Pharmaceutics, MDPI, 2021, 13 (5), pp.601. ⟨10.3390/pharmaceutics13050601⟩
Volume 13
Issue 5
Pharmaceutics, Vol 13, Iss 601, p 601 (2021)
Pharmaceutics, 2021, 13 (5), pp.601. ⟨10.3390/pharmaceutics13050601⟩
Pharmaceutics, MDPI, 2021, 13 (5), pp.601. ⟨10.3390/pharmaceutics13050601⟩
Volume 13
Issue 5
Pharmaceutics, Vol 13, Iss 601, p 601 (2021)
International audience; The treatment of respiratory tract infections is threatened by the emergence of bacterial resistance. Immunomodulatory drugs, which enhance airway innate immune defenses, may improve therapeutic outcome. In this concept paper,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::0f3eced2285c88bd0176ee44f3c043fc
https://hal.sorbonne-universite.fr/hal-03215662
https://hal.sorbonne-universite.fr/hal-03215662
Autor:
Franck, Sebastian, Michelet, Robin, Casilag, Fiordiligie, Sirard, Jean Claude, Wicha, Sebastian, Kloft, Charlotte
Publikováno v:
Pharmaceutics
Volume 13
Issue 4
Pharmaceutics, Vol 13, Iss 469, p 469 (2021)
Pharmaceutics, 2021, 13 (4), pp.1-12. ⟨10.3390/pharmaceutics13040469⟩
Pharmaceutics, MDPI, 2021, 13 (4), pp.1-12. ⟨10.3390/pharmaceutics13040469⟩
Volume 13
Issue 4
Pharmaceutics, Vol 13, Iss 469, p 469 (2021)
Pharmaceutics, 2021, 13 (4), pp.1-12. ⟨10.3390/pharmaceutics13040469⟩
Pharmaceutics, MDPI, 2021, 13 (4), pp.1-12. ⟨10.3390/pharmaceutics13040469⟩
Corresponding author: Charlotte Kloft (charlotte.kloft@fu-berlin.de); International audience; Combining amoxicillin with the immunostimulatory toll-like receptor 4 agonist monophosphoryl lipid A (MPLA) represents an innovative approach for enhancing
Autor:
Franck, Sebastian Niklas
Therapy of bacterial infectious diseases is an increasingly challenging task due to the emergence of resistance, which has become a major threat for global healthcare in the last years. In particular, lower respiratory tract infections are contributi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::233fb63f3e81fbb1391a8d46839bb91d